Cleviprex
(Clevidipine)ApprovedSmall molecule
Chiesi Farmaceutici S.p.A.Clevidipine is used to lower high blood pressure quickly in hospitalized patients when oral medications cannot be used. It works by relaxing blood vessels to help reduce blood pressure.[2] Cleviprex is currently approved and in use across 6 indications[4].[1]
Cleviprex is one of 121 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
6
Indications
23
Total Trials
2
Active Trials
120
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
157 competitors in Hypertension
#DrugCompanyPhaseTrials
1Cleviprex
Chiesi Farmaceutici S.p.A.Approved
Foundayo
Eli LillyPhase 3
Alka-Seltzer
AAbbott
Phase 3
Minocycline /d
UUniversity of Florida
Phase 3
HCP1803-3
Hanmi Pharmaceutical Company LimitedPhase 3
Avastin
RochePreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Nipride
EExela Pharma Sciences, LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypertension5 trials
Cardiac Surgery3 trials
Intracerebral Hemorrhage2 trials
Safety and Efficacy1 trial
A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT)
Terminated·—·Phase 4·NCT01033370·5 enrolled
11 more indications
Pediatric1 trial
Ischemic stroke1 trial
Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke
Completed·—·Phase 3·NCT05175547·80 enrolled
Aortic Aneurysm1 trial
Neurosurgical Patients1 trial
Heart Failure1 trial
Hypertensive1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Aug 1, 2008
CLEVIPREX
NDA NDA022156
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Cleviprex drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Clevidipine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Voltage-Gated L-Type Calcium Channel Blocker[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company